Takeda Pharmaceutical (TAK) Short term Debt: 2018-2025

Historic Short term Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $3.6 billion.

  • Takeda Pharmaceutical's Short term Debt rose 45.19% to $3.6 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.6 billion, marking a year-over-year increase of 45.19%. This contributed to the annual value of $3.6 billion for FY2025, which is 41.51% up from last year.
  • According to the latest figures from FY2025, Takeda Pharmaceutical's Short term Debt is $3.6 billion, which was up 41.51% from $2.5 billion recorded in FY2024.
  • In the past 5 years, Takeda Pharmaceutical's Short term Debt registered a high of $3.6 billion during FY2025, and its lowest value of $1.8 billion during FY2022.
  • In the last 3 years, Takeda Pharmaceutical's Short term Debt had a median value of $2.5 billion in 2024 and averaged $2.9 billion.
  • Its Short term Debt has fluctuated over the past 5 years, first slumped by 56.66% in 2021, then soared by 41.51% in 2025.
  • Takeda Pharmaceutical's Short term Debt (Yearly) stood at $2.3 billion in 2021, then fell by 22.35% to $1.8 billion in 2022, then surged by 38.35% to $2.5 billion in 2023, then grew by 1.30% to $2.5 billion in 2024, then spiked by 41.51% to $3.6 billion in 2025.